Whether the immuno-oncology drug combination of Imfinzi and Imjudo will gain a place as a treatment option for liver cancer in Korea is gaining attention.

AstraZeneca Korea's combination therapy of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA-4 inhibitor Imjudo (tremelimumab) recently passed the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review and is headed towards a Drug Reimbursement Evaluation Committee review.

Given that the application was submitted in June, this is a relatively fast track reaching coverage in Korea, which is why the industry’s eyes are on how quickly the combination therapy will be approved for reimbursement.<